drugset / Trial / NCT06543069
Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM
NaSingle-groupOpen-labelTreatment
Summary
To explore the efficacy and safety of sintilimab, bevacizumab combined with pemetrexed and cisplatin in the treatment of malignant peritoneal mesothelioma, and to explore the biomarkers related to efficacy or safety.
Timeline
- Start
- 2024-01-31
- Primary completion
- 2026-01-31
- Completion
- 2027-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | — |
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | — |
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | — |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | — |